Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2011 (Earliest event reported)
Reporting Period: Events occurring on September 25 and 26, 2011.
Key Financial Metrics and Transactions
This filing reports a material financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow). The filing text does not provide current revenue, profit, margin, or debt figures.
- Financing Amount: $7,500,000 aggregate purchase price.
- Investor: Kissei Pharmaceutical Co. Ltd.
- Common Stock Issued: 800,000 shares at $2.50 per share.
- Preferred Stock Issued: 220,000 shares of Series B Convertible Preferred Stock at $25.00 per share.
- Preferred Stock Conversion: Initially convertible at a rate of 10 shares of Common Stock for each share of Series B Preferred.
Material Changes and Corporate Actions
Material Definitive Agreement
On September 26, 2011, the Company entered into a Stock Purchase Agreement with Kissei. Key terms include:
- Standstill Agreement: Kissei agreed to a standstill prohibiting additional purchases, tender offers, proxy solicitations, or hostile activities without Board approval. This terminates if Kissei's beneficial ownership drops below 3%.
- Notification Rights: The Company must notify and consult Kissei regarding any process to sell the Company or negotiations regarding an unsolicited acquisition bid.
- Preferred Stock Rights: Series B Preferred ranks pari passu with Common Stock on liquidation. It carries no voting rights unless required by law or for specific actions affecting its seniority. It has no redemption rights.
Board of Directors Changes
- Appointment: The Board size increased from five to six. Tatsuo Izumi was elected to the new vacancy on September 25, 2011. He received a fully vested option to purchase 15,000 shares.
- Resignation: John K.A. Prendergast, Ph.D., resigned from the Board and all committee memberships (including Audit Committee Chairman) effective September 26, 2011. The resignation was not due to any disagreement with the Company.
- Committee Update: Jeff Himawan, Ph.D., was appointed interim-Chairman of the Audit Committee.
- Closing Conditions: The sale of shares to Kissei is subject to the satisfaction of certain closing conditions.
- Representations: The filing explicitly states that representations and warranties in the Purchase Agreement are for risk allocation and closing conditions only, are not necessarily accurate or complete, and should not be relied upon by stockholders.
- Verify the closing status of the $7.5 million financing with Kissei Pharmaceutical Co. Ltd.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for detailed rights of the Series B Convertible Preferred Stock.
- Confirm the impact of the 800,000 new common shares and potential conversion of 220,000 preferred shares (up to 2.2 million common shares) on existing shareholder dilution.
- Monitor the composition of the Audit Committee following Dr. Prendergast's resignation.
- Check for any subsequent filings regarding the satisfaction of closing conditions for the Kissei transaction.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary on future financial performance.
Risks and Contingencies: